Teva Pharmaceutical Industries (TEVA) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
3 Nov, 2026Executive summary
Q3 revenue was $4.395B, down 2% YoY; innovative brands grew 33% in local currency, partly offsetting lower generic revenue, led by lenalidomide erosion.
Non-GAAP gross margin rose to 58.7% (+345 bps) and non-GAAP EPS to $0.86 (+10%); GAAP net income was $233M versus $433M a year earlier.
2026 revenue and key brand outlooks were raised; WELTRUZA approval, biosimilar partnerships and pipeline progress supported the growth strategy.
Financial highlights
GAAP gross profit rose 6% to $2.440B and gross margin was 55.5% versus 51.4%; GAAP operating income was $714M versus $882M.
Non-GAAP operating income was $1.393B (+8%), with a 31.7% margin (+282 bps); non-GAAP net income was $1.013B and diluted EPS $0.86 versus $0.78.
Adjusted EBITDA grew 7% to $1.496B; free cash flow was $495M (-4%), while Q3 YTD free cash flow reached $1.305B (+19%).
Q3 revenue was $4.395B; 9M revenue was $12.519B, flat YoY, while 9M net income attributable fell to $26M from $930M.
Outlook and guidance
FY2026 revenue guidance rose to $16.7B-$17.0B; non-GAAP operating income is $3.8B-$3.9B and adjusted EBITDA $4.23B-$4.43B.
FY2026 diluted EPS guidance is $1.92-$2.11 and free cash flow $2.1B-$2.4B; guidance includes $0.87B acquired IPR&D charges in operating income and EBITDA.
2026 outlooks rose to $2.55B-$2.65B for AUSTEDO, $930M-$960M for AJOVY and $290M-$310M for UZEDY.
2027 targets include mid-single-digit 2023-27 revenue CAGR, 30% non-GAAP operating margin, 2.0x net debt/adjusted EBITDA and 80% cash-to-earnings; gross margin outlook is 57%-58%.
Transformation programs target ~$700M net savings and an ~8% workforce reduction from the 2024 baseline by end-2027; two-thirds of savings are expected in 2026.
Latest events from Teva Pharmaceutical Industries
- A 10-asset pipeline supports a $6B–$7B innovative revenue target by 2030.TEVA
R&D Day 2026 - Revenue grew 6%, supported by growth brands and a $500M anti-TL1A payment, as debt declined.TEVA
Q4 2023 - FDA approves WELTRUZA, a once-monthly olanzapine LAI for adults with schizophrenia.TEVA
FDA announcement - Investment grade status enables accelerated innovation, robust launches, and renewed generics growth.TEVA
Bank of America Global Healthcare Conference - Biopharma transformation drives growth, margin expansion, and robust pipeline execution.TEVA
U.S. All Stars Conference - Biopharma transformation accelerates as innovative launches and biosimilars drive growth.TEVA
Barclays 24th Annual Global Financial Services Conference - Growth strategy delivers early milestones, with innovative products and biosimilars driving future value.TEVA
Morgan Stanley 24th Annual Global Healthcare Conference - TEV-408 significantly prevented gluten-induced intestinal damage and improved symptoms in celiac disease.TEVA
Study result - Innovative brands surged 43% YoY, offsetting generics decline, with 2026 outlook raised.TEVA
Q2 2026